1.
2.
Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors
by Lenardo, Michael
Nature medicine, 2005, Vol.11 (10), p.1066-1072
4.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, doubl...
by Nash, Peter, Prof
The Lancet (British edition), 2017, Vol.389 (10086), p.2317-2327
5.
Necroptosis and Inflammation
by Newton, Kim
Annual review of biochemistry, 2016, Vol.85 (1), p.743-763
6.
Synaptic scaling mediated by glial TNF-α
by Malenka, Robert C
Nature, 2006, Vol.440 (7087), p.1054-1059
7.
Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene
by Ravet, N
Annals of the rheumatic diseases, 2006, Vol.65 (9), p.1158-1162
8.
BAFF AND APRIL: A Tutorial on B Cell Survival
by Mackay, Fabienne
Annual review of immunology, 2003, Vol.21 (1), p.231-264
9.
CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis
by Zhang, Ting
Nature medicine, 2016, Vol.22 (2), p.175-182
10.
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
by Cruyssen, Bert Vander
Annals of the rheumatic diseases, 2007, Vol.66 (8), p.1072-1077
11.
TNF/TNFR family members in costimulation of T cell responses
by Watts, Tania H
Annual review of immunology, 2005, Vol.23 (1), p.23-68
12.
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
by Salmon-Ceron, D
Annals of the rheumatic diseases, 2011, Vol.70 (4), p.616-623
13.
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
by Gardam, Michael A
The Lancet infectious diseases, 2003, Vol.3 (3), p.148-155
14.
Tumor necrosis factor and cancer, buddies or foes
by WANG, Xia
Acta pharmacologica Sinica, 2008, Vol.29 (11), p.1275-1288
15.
The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferenti...
by Lie, Elisabeth
Annals of the rheumatic diseases, 2015, Vol.74 (6), p.970-978
16.
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
by Mariette, Xavier
Annals of the rheumatic diseases, 2011, Vol.70 (11), p.1895-1904
17.
Soluble tumor necrosis factor receptor 1 is associated with diminished estimated glomerular filtration rate in colombian patients with type 2 diabetes
by Gómez-Banoy, Nicolás
Journal of diabetes and its complications, 2016, Vol.30 (5), p.852-857
18.
Single Intradiscal Administration of the Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, for Patients with Discogenic Low Back Pain
by Sainoh, Takeshi
Pain medicine (Malden, Mass.), 2016, Vol.17 (1), p.40-45
19.
Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor–Alpha Experienced Rheumatoid Arthritis
by Wells, Alvin F
Clinical therapeutics, 2017, Vol.39 (8), p.1680-1694.e2
20.
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
by Hotamisligil, Gkhan S
Nature (London), 1997, Vol.389 (6651), p.610-614
